证券代码：300501 证券简称：海顺新材 上海海顺新型药用包装材料股份有限公司投资者关系活动记录表 编号：2021-012 | --- | --- | --- | |----------------|------------------------------------------------------------------------------------------------------|--------------------------------------------------------| | | ☑ 特定对象调研 □分析师会议 \n□媒体采访 □业绩说明会 \n□新闻发布会 \n□现场参观 \n□其他：线上交流活动 | □路演活动 | | | 中泰证券 — 陈沁一、郭中伟 | | | 参与单位名称及 | 德邦证券 — | 华小伟、毕光磊、李珏晗 | | 人员姓名 | 复星集团 — 操宇、李贺 | | | | 中信资本 — 周伟峰 | | | 时间 | 2021 年 09 月 16 日 | | | 地点 | 公司大会议室 | | | 上市公司接待人 | 董事长、总经理—林武辉 | ...

证券代码：300501 证券简称：海顺新材 上海海顺新型药用包装材料股份有限公司投资者关系活动记录表 编号：2021-007 | --- | --- | --- | |--------------------|------------------------------------------------------------------------------------------------------|-----------------------------------------------------------| | | ☑ 特定对象调研 □分析师会议 \n□媒体采访 □业绩说明会 \n□新闻发布会 \n□现场参观 \n□其他：线上交流活动 | □路演活动 | | | 前海开源基金—张伟、薛晋伟 | | | 参 与 单位 名称 及 | 乘安资产—袁晓栋、王镜程 | | | 人员姓名 | 国禹资产—杨金同 | | | | 钜鑫资本—贾兴亮 | | | 时间 | 2021 年 07 月 13 日 | 14: 00-16: 00 | | 地点 | 公司会议室 | | | 上 市 公司 接待 人 | ...

Group 1: Company Overview - Shanghai Haishun New Material Co., Ltd. has been deeply engaged in the pharmaceutical packaging industry for over a decade, achieving significant results, particularly in solid drug packaging [1] - As of mid-2021, the company holds 115 registration numbers in the pharmaceutical packaging sector, indicating a competitive edge [1] - The company aims to expand its scale and has developed a clear growth strategy focused on revenue and profit [1] Group 2: Market Segments - The first segment is the pharmaceutical packaging sector, where the company has established relationships with over 2,000 enterprises and has issued over 3,000 authorization letters in the past three years [2] - The second segment focuses on consumer packaging, where the company is exploring new opportunities, including partnerships with Mengniu and tobacco companies [2] - The third segment involves new energy packaging, specifically aluminum-plastic films for soft-pack lithium batteries, with a planned production capacity of 20 million square meters [3] Group 3: Production and Capacity - The company plans to install and commission new production lines by the end of 2021, with a focus on aluminum-plastic film production to meet the growing demand in the new energy sector [3] - The company has also established a dedicated team for consumer products, leveraging long-term technical accumulation to facilitate product development [2] - Current production capacity utilization is nearly saturated, with ongoing investments based on customer demand [6] Group 4: Financial Performance and Strategy - The company's gross profit margin was approximately 29% in the second and third quarters of 2021, with fluctuations expected based on raw material prices and product mix [6] - The company aims to maintain revenue growth in its pharmaceutical packaging segment, which is expected to remain a significant portion of total business by 2025 [7] - The company is actively working to mitigate the impact of rising raw material costs by introducing new products to existing customers and acquiring new clients through marketing efforts [6] Group 5: Competitive Landscape - The pharmaceutical packaging market is characterized by intense competition, with many small and medium-sized enterprises [5] - The company recognizes the importance of product quality and scale advantages in the competitive landscape of aluminum-plastic films [3] - The company is also exploring the potential of recyclable high-barrier composite materials in response to evolving market demands [4]

Group 1: New Consumer Market Expansion - The company has established a partnership with Mengniu for the cheese stick project, which began large-scale supply in July 2021, indicating a positive growth trajectory in the new consumer sector [3][4]. - The cheese stick packaging production line has been expanded to enhance production efficiency and product quality stability [3][4]. - The company aims to capture growth in the cheese stick niche market, with expectations of continued growth in the coming years due to increased investments from major dairy companies [4]. Group 2: Competitive Landscape - There are approximately 10 domestic competitors capable of producing PS sheets, but only 3 to 5 are considered truly competitive based on capacity and quality stability [4]. - The company adheres to GMP standards for production, leveraging years of technical expertise and service experience to maintain a competitive edge [4]. Group 3: Supply Chain and Raw Material Challenges - Fluctuations in raw material prices have impacted profit stability, with significant increases observed this year [5]. - The company is focused on maintaining communication with long-term clients to mitigate the impact of rising raw material costs, while also exploring ways to reduce these impacts [5]. - The company plans to extend its supply chain and increase the number of suppliers to ensure supply chain security [4][5]. Group 4: Future Business Projections - The company projects that the pharmaceutical packaging segment will decrease to less than 50% of total business in the future, with new consumer sectors like cheese sticks and electronic cigarettes expected to grow significantly [5][6]. - The company aims to achieve a scale of 400 to 500 million in the new consumer market [6].

证券代码：300501 证券简称：海顺新材 上海海顺新型药用包装材料股份有限公司投资者关系活动记录表 编号：2022-004 | --- | --- | --- | |-------------------------|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------| | | ☑ 特定对象调研 | □分析师会议 | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | 类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他：线上交流活动 | | | 参与单位名称及 人员姓名 | 诺安基金——王晴 | | | 时间 | 2022 年 11 月 10 日（周四） | 14:00 — 15:00 | | 地点 | 公司大会议室 | | | 上市公司 ...

，证券代码：300501 证券简称：海顺新材 上海海顺新型药用包装材料股份有限公司投资者关系活动记录表 编号：2022-005 | --- | --- | --- | |-------------------------|---------------------------------------|------------------------------------------------------------------------------------------------------------| | | ☑ 特定对象调研 □分析师会议 | | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | 类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他：线上交流活动 | | | 参与单位名称及 人员姓名 | 东北证券——莫然 汇丰普信基金——赵洋 | | | 时间 | 2022 年 11 月 11 日（周五） | 10:00 — 11:00 | | 地点 | 公司大会议室 | | | 上市公司接待人 员姓名 | 董事会秘书—杨高锋 证券事务助理—叶骏超 ...

证券代码：300501 证券简称：海顺新材 上海海顺新型药用包装材料股份有限公司投资者关系活动记录表 编号：2022-003 | --- | --- | --- | |-------------------------|---------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | ☑ 特定对象调研 | □分析师会议 | | 投资者关系活动 | □媒体采访 □业绩说明会 | | | 类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他：线上交流活动 | | | 参与单位名称及 人员姓名 | 常春藤 ...

Financial Performance - The company's revenue for Q3 2022 reached ¥233,861,160.04, representing a 21.58% increase compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2022 was ¥28,254,137.51, up 38.76% year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥25,907,474.27, an increase of 31.07% compared to the previous year[5] - The basic earnings per share for Q3 2022 was ¥0.15, a 15.38% increase year-on-year[5] - Net profit for Q3 2022 was ¥88,248,593.08, representing a growth of 8.1% from ¥81,597,542.92 in Q3 2021[25] - Earnings per share (EPS) for Q3 2022 was ¥0.43, a decrease from ¥0.51 in the same quarter last year[26] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥2,364,710,525.62, reflecting a 4.45% increase from the end of the previous year[5] - The total equity attributable to shareholders at the end of Q3 2022 was ¥1,577,427,986.85, a 4.47% increase from the previous year-end[5] - The total liabilities increased to ¥706,767,066.75 from ¥678,549,169.20 year-over-year, reflecting a rise of 4.3%[25] - The total current liabilities increased to CNY 548,738,504.39 from CNY 489,890,389.72, showing an increase of approximately 11.9%[21] - Long-term borrowings decreased to CNY 125,180,446.82 from CNY 164,530,563.84, indicating a reduction of about 23.9%[21] Cash Flow - The cash flow from operating activities for the year-to-date period decreased by 63.25% to ¥53,983,974.44[5] - Cash flow from operating activities generated a net amount of ¥53,983,974.44, down from ¥146,886,818.39 in Q3 2021[27] - The company reported a net cash outflow from investment activities of CNY 277.17 million, a 43.25% increase compared to the previous year[12] - The cash inflow from operating activities totaled ¥771,067,723.75, compared to ¥750,626,699.29 in the previous year, indicating a slight increase of 2.9%[27] - The net cash flow from investment activities was -¥277,168,363.78, compared to -¥193,488,810.70 in the previous year, indicating a decline of approximately 43.4%[29] - The total cash inflow from financing activities was ¥107,846,149.07, a significant decrease of 87.2% from ¥839,813,241.73 in the same period last year[29] - The net cash flow from financing activities was -¥82,212,385.12, contrasting sharply with a positive net flow of ¥660,481,320.43 in the previous year[29] Investments and Expenses - Research and development expenses grew by 48.46% to CNY 30.89 million, reflecting increased investment in R&D[11] - Research and development expenses increased to ¥30,889,093.53, a rise of 48.5% compared to ¥20,806,731.30 in the previous year[24] - The company reported a decrease in financial expenses, showing a net income of -¥11,449,385.79 compared to a positive income of ¥2,730,833.43 in Q3 2021[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,064[14] - The largest shareholder, Lin Wuhui, holds 29.98% of the shares, amounting to 58,019,499 shares[14] Other Information - The company received government subsidies amounting to ¥3,286,844.22 during the reporting period[6] - The company issued convertible bonds on July 14, 2022, which were accepted by the Shenzhen Stock Exchange, indicating a strategic move to raise capital[17] - The company responded to an inquiry from the Shenzhen Stock Exchange regarding the issuance of convertible bonds on August 9, 2022, demonstrating proactive communication with regulators[17] - The company is actively engaged in the development of new products and technologies, although specific details were not disclosed in the report[19] - The company did not conduct an audit for the third quarter report, as indicated in the audit report section[30] - The company experienced a foreign exchange impact on cash and cash equivalents of ¥5,989,649.77, compared to -¥319,017.85 in the previous year[29]

Financial Performance - The company reported a revenue of 300 million RMB for the first half of 2022, representing a year-on-year increase of 15%[13] - The company's revenue for the reporting period was ¥480,135,188.73, representing an increase of 11.93% compared to ¥428,971,227.44 in the same period last year[19] - The company achieved operating revenue of 48,013.52 million yuan, representing a year-on-year growth of 11.93%[37] - The company reported a total revenue of 8.9 million yuan, indicating a significant change in financial performance[170] - The total revenue for the first half of 2022 was 1,347.4 million yuan, showing an increase compared to the previous year's 638.6 million yuan, representing a growth of approximately 110%[173] Profitability - Net profit attributable to shareholders decreased by 6.14% to ¥55,021,006.98 from ¥58,620,084.28 year-on-year[19] - The company reported a net profit of CNY 58,662,833.57, a decrease of 3.0% from CNY 60,417,659.66 in the previous year[154] - The company's total comprehensive income for the first half of 2022 was CNY 1,652,652.23, reflecting a decrease of 59.2% compared to CNY 4,047,487.32 in the previous year[158] - The net profit for the first half of 2022 was CNY 1,652,652.23, down 59.2% from CNY 4,047,487.32 in the first half of 2021[158] - Basic and diluted earnings per share fell by 24.32% to ¥0.28 from ¥0.37 in the same period last year[19] Research and Development - The company plans to invest 50 million RMB in R&D for new packaging technologies in the upcoming year[13] - R&D investment grew by 51.63% year-on-year, with 25 new patents and 13 new drug packaging material registration numbers added in the first half of the year[38] - The company's research and development investment increased by 51.63% to ¥23,287,264.65, up from ¥15,358,153.17, reflecting a stronger focus on product development[44] - The company is focusing on the development of high-barrier, low-adsorption, and low-migration packaging materials for the pharmaceutical industry, enhancing its product range and market competitiveness[27] - The company is committed to continuous technological innovation and product structure adjustment to enhance core competitiveness in response to market challenges[71] Market Expansion - User data indicates a 20% increase in customer base, reaching 1,200 active clients[13] - The company has expanded its market presence in Europe, with sales in that region growing by 25%[13] - The company is actively expanding its overseas business, with foreign sales and procurement primarily in USD and EUR, exposing it to exchange rate risks[74] - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not mentioned in the provided data[164] - The company plans to enhance its market expansion strategies and invest in new product development to drive future growth[171] Financial Position - The total assets increased by 4.78% to ¥2,372,186,518.46 from ¥2,264,050,337.46 at the end of the previous year[19] - The company's cash and cash equivalents decreased significantly by 2,800.40% to -¥213,633,295.93, compared to an increase of ¥7,911,159.66 in the previous year[45] - The company's total assets at the end of the reporting period amounted to 823.9 million yuan, up from 263.2 million yuan in the same period last year, indicating a growth of about 213%[176] - The total equity attributable to owners at the end of the period was 1,333.29 million yuan, up from 638.6 million yuan in the previous year, representing an increase of approximately 108%[175] - The company's total liabilities rose from CNY 678,549,169.20 to CNY 743,825,132.01, reflecting an increase of approximately 9.63%[146] Cash Flow - The net cash flow from operating activities dropped significantly by 76.69%, amounting to ¥19,995,507.24 compared to ¥85,782,233.76 in the previous year[19] - Cash flow from operating activities generated a net amount of CNY 19,995,507.24, a significant decline of 76.7% compared to CNY 85,782,233.76 in the previous year[159] - The company reported a net cash outflow from investing activities of CNY 215,006,579.10, compared to a net outflow of CNY 120,513,113.78 in the same period last year[161] - The cash flow from financing activities showed a net outflow of CNY 22,041,202.89, contrasting with a net inflow of CNY 43,122,313.73 in the first half of 2021[161] - The total cash inflow from financing activities was CNY 33,868,200.38, up from CNY 28,570,000.00 in the previous period, while cash outflows were CNY 52,910,445.49, down from CNY 61,909,610.98[164] Strategic Initiatives - The company is exploring potential acquisitions to enhance its product offerings and market reach[13] - The company has made strategic acquisitions, including a 68% stake in Duoling Pharmaceutical Packaging in August 2016 and a 100% stake in Suzhou Qingyi in March 2017, enhancing market presence and profitability[73] - The company is focusing on strategic mergers and acquisitions to strengthen its market presence[171] - The company aims to improve operational efficiency through policy changes and error corrections in financial reporting[171] - The company has initiated a new technology research and development program aimed at improving packaging materials[171] Corporate Governance - The company adheres to legal regulations and has improved its corporate governance structure to protect shareholder rights, ensuring accurate and timely information disclosure[93] - The company has implemented a stable profit distribution policy to secure shareholder returns and has no instances of major shareholders or related parties misusing company funds during the reporting period[93] - The company actively engages in investor relations management, utilizing multiple channels to enhance investor awareness and protect their rights[95] - The company has confirmed that there are no significant doubts regarding its ability to continue as a going concern for the next 12 months[181] - The financial statements are prepared in accordance with the enterprise accounting standards, reflecting the company's financial position, operating results, and cash flows accurately[183] Environmental and Social Responsibility - The company has no environmental penalties during the reporting period and adheres to national and local environmental regulations[89] - The company is committed to sustainable development, focusing on economic benefits while fulfilling social responsibilities[92] - The company has implemented measures to reduce carbon emissions, including the use of low-nitrogen burners and waste gas treatment systems[91] - The company has participated in charitable activities, including donations to educational institutions, while balancing economic benefits with social responsibilities[96] - The company emphasizes the importance of integrating corporate culture and management systems post-acquisition to realize expected investment returns[73]

Financial Performance - Revenue for Q1 2022 was CNY 231,871,055.84, an increase of 3.57% compared to CNY 223,874,529.01 in the same period last year[4] - Net profit attributable to shareholders decreased by 24.13% to CNY 25,483,174.76 from CNY 33,586,697.68 year-on-year[4] - Basic earnings per share fell by 38.10% to CNY 0.13 from CNY 0.21 in the same period last year[4] - The net profit for Q1 2022 was CNY 27,050,277.66, a decrease of 21.1% from CNY 34,217,622.40 in Q1 2021[24] - The profit attributable to the parent company's shareholders was CNY 25,483,174.76, down 24.2% from CNY 33,586,697.68 in the previous year[24] - The total comprehensive income for the first quarter was CNY 27,050,277.66, a decrease from CNY 34,217,622.40 in the previous year, representing a decline of approximately 21%[25] Cash Flow and Liquidity - Net cash flow from operating activities was negative at CNY -39,061,737.17, a decline of 209.64% compared to CNY 35,626,124.72 in the previous year[4] - Cash inflow from operating activities totaled CNY 179,921,854.94, down from CNY 219,412,068.25, indicating a decrease of about 18%[27] - The company reported cash outflows from operating activities of CNY 218,983,592.11, an increase of approximately 19% from CNY 183,785,943.53 in the previous year[27] - The cash and cash equivalents at the end of the period were CNY 435,806,092.42, a significant increase of 358.06% from CNY 95,140,921.56 at the end of the previous year[9] - The company reported cash and cash equivalents of ¥457,017,550.08 at the end of the period, down from ¥633,853,715.33 at the beginning of the year[17] Assets and Liabilities - Total assets increased by 2.35% to CNY 2,317,309,669.68 from CNY 2,264,050,337.46 at the end of the previous year[4] - The total liabilities increased to CNY 697,322,406.15, up from CNY 678,549,169.20, representing a rise of 2.3%[19] - The inventory level was CNY 162,539,558.44, slightly up from CNY 160,744,669.02, showing a marginal increase of 1.1%[18] Investment Activities - Investment activities generated a net cash outflow of CNY -129,754,726.70, an increase of 103.68% compared to CNY -63,704,263.81 in the previous year[9] - The total cash inflow from investment activities was CNY 36,485,924.01, down from CNY 55,361,561.05, indicating a decline of about 34%[27] Shareholder Information - Total number of common shareholders at the end of the reporting period is 14,934[11] - The largest shareholder, Lin Wuhui, holds 29.98% of shares, totaling 58,019,499 shares, with 9,800,000 shares pledged[11] - The top ten shareholders include Zhu Xiumei with 16.65% ownership, totaling 32,230,408 shares[11] - The total number of restricted shares at the end of the period is 68,494,869, with 1,379,250 shares released and 429,750 shares newly restricted during the period[15] - The company has a total of 69,444,369 restricted shares, with various executives holding significant amounts[15] Operational Insights - The company is focused on expanding its market presence and developing new products in the pharmaceutical packaging sector[12] - The management emphasizes the importance of innovation in product development to maintain competitive advantage[12] - The company plans to continue its strategy of shareholder engagement and potential future capital raises[12] Costs and Expenses - The total operating costs for Q1 2022 amounted to CNY 201,369,862.48, up 8.5% from CNY 185,596,469.38 year-over-year[22] - Research and development expenses for Q1 2022 were CNY 7,732,996.71, an increase of 26.0% from CNY 6,138,998.03 in the same period last year[22] - The company reported a financial cost of CNY -1,904,352.15, which is a decrease compared to CNY -803,402.29 in the previous year, indicating improved financial management[22] - The company reported a significant increase in cash paid for purchasing goods and services, totaling CNY 151,465,112.46, compared to CNY 127,487,870.31 in the previous year, an increase of approximately 19%[27] Credit and Impairment - The company experienced a 2959.03% increase in credit impairment losses, amounting to CNY -1,901,408.34, primarily due to increased bad debt provisions[8]